Free Trial

Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update

Novozymes A/S logo with Basic Materials background

Key Points

  • Short Interest Decrease: Novozymes A/S saw a significant drop in short interest, falling 87.8% from 52,500 shares in August to 6,400 shares by September 15th.
  • Analyst Downgrade: Zacks Research downgraded Novozymes A/S from a "strong-buy" to a "hold" rating, with the stock currently holding a consensus rating of "Hold".
  • Dividend and Payout Ratio: The company recently cut its dividend to $0.1856 per share, reflecting a yield of 88.0% and a payout ratio of 23.42%.
  • Five stocks to consider instead of Novozymes A/S.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a significant decrease in short interest in September. As of September 15th, there was short interest totaling 6,400 shares, a decrease of 87.8% from the August 31st total of 52,500 shares. Based on an average daily trading volume, of 100,000 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 100,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Novozymes A/S from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold".

View Our Latest Research Report on Novozymes A/S

Novozymes A/S Stock Up 1.9%

NVZMY stock traded up $1.13 during midday trading on Tuesday, reaching $61.17. The company had a trading volume of 25,920 shares, compared to its average volume of 39,748. The company has a 50 day moving average of $64.22 and a two-hundred day moving average of $65.81. The company has a current ratio of 1.75, a quick ratio of 1.07 and a debt-to-equity ratio of 0.28. Novozymes A/S has a 1 year low of $53.95 and a 1 year high of $75.99. The company has a market capitalization of $28.65 billion, a P/E ratio of 38.72, a PEG ratio of 1.15 and a beta of 0.93.

Novozymes A/S Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, September 11th. Investors of record on Wednesday, September 3rd were issued a $0.1856 dividend. The ex-dividend date was Tuesday, September 2nd. This represents a yield of 88.0%. Novozymes A/S's dividend payout ratio is currently 23.42%.

About Novozymes A/S

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novozymes A/S Right Now?

Before you consider Novozymes A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.

While Novozymes A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.